2.P.79 Cholesteryl ester storage disease: Molecular defects and treatment with the HMGCoA-reductase inhibitor lovastatin

1997 ◽  
Vol 134 (1-2) ◽  
pp. 132-133
Author(s):  
F. Rassoul ◽  
E. Keller ◽  
A. Naumann ◽  
P. Lohse ◽  
K. Purschwitz ◽  
...  
Keyword(s):  
Cholesteryl Ester ◽  
Reductase Inhibitor ◽  
Storage Disease ◽  
Hmgcoa Reductase ◽  
Molecular Defects ◽  
Hmgcoa Reductase Inhibitor

scholarly journals Molecular defects underlying Wolman disease appear to be more heterogeneous than those resulting in cholesteryl ester storage disease

1999 ◽  
Vol 40 (2) ◽  
pp. 221-228 ◽  
Author(s):  
Peter Lohse ◽  
Sylke Maas ◽  
Pia Lohse ◽  
Adrian C. Sewell ◽  
Otto P. van Diggelen ◽  
...  
Keyword(s):  
Cholesteryl Ester ◽  
Storage Disease ◽  
Wolman Disease ◽  
Molecular Defects

Is fat restriction needed with HMGCoA reductase inhibitor treatment?

1992 ◽  
Vol 93 (1-2) ◽  
pp. 59-70 ◽  
Author(s):  
Peter M. Clifton ◽  
Marion B. Wight ◽  
Paul J. Nestel
Keyword(s):  
Reductase Inhibitor ◽  
Hmgcoa Reductase ◽  
Hmgcoa Reductase Inhibitor ◽  
Inhibitor Treatment

Cholesteryl Ester Storage Disease: Relationship between Molecular Defects andin SituActivity of Lysosomal Acid Lipase

1997 ◽  
Vol 62 (1) ◽  
pp. 42-49 ◽  
Author(s):  
Isabelle Redonnet-Vernhet ◽  
Martine Chatelut ◽  
Jean-Pierre Basile ◽  
Robert Salvayre ◽  
Thierry Levade
Keyword(s):  
Cholesteryl Ester ◽  
Storage Disease ◽  
Acid Lipase ◽  
Lysosomal Acid ◽  
Molecular Defects ◽  
Lysosomal Acid Lipase

scholarly journals Compound heterozygosity for a Wolman mutation is frequent among patients with cholesteryl ester storage disease

2000 ◽  
Vol 41 (1) ◽  
pp. 23-31
Author(s):  
Peter Lohse ◽  
Sylke Maas ◽  
Pia Lohse ◽  
Milan Elleder ◽  
Jean M. Kirk ◽  
...  
Keyword(s):  
Cholesteryl Ester ◽  
Storage Disease ◽  
Compound Heterozygosity
Sign in / Sign up

Export Citation Format

Share Document